Overview

We have considered as examples for the proof of principle two different diseases that could be treated by the use of our synthetic microencapsulated cellular device (Figure 1):

• The therapy of hepatitis C by the local production of interferon alpha followed by the production of hepatocyte growth factor, providing a regeneration step.
• The therapy of ischaemic heart disease with anakinra as an antiinflammatory agent, while vascular endothelial growth factor and platelet-derived growth factor, produced in stoichiometric amounts enhance angiogenesis and tissue oxigenation.

Figure 1. The proposed therapeutic implementations of our synthetic biology device.

Figure 1. The proposed therapeutic implementations of our synthetic biology device.

Advantages